Publication: Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort
dc.contributor.author | İdilman, Ramazan | |
dc.contributor.author | Demir, Mehmet | |
dc.contributor.author | Aladağ, Murat | |
dc.contributor.author | Erol, Cihan | |
dc.contributor.author | Çavuş, Bilger | |
dc.contributor.author | İliaz, Raim | |
dc.contributor.author | Köklü, Hayrettin | |
dc.contributor.author | Çakaloğlu, Yılmaz | |
dc.contributor.author | Şahin, Memduh | |
dc.contributor.author | Ersöz, Galip | |
dc.contributor.author | Köksal, İftihar | |
dc.contributor.author | Karasu, Zeki | |
dc.contributor.author | Özgenel, Meriç | |
dc.contributor.author | Turan, İlker | |
dc.contributor.author | Gündüz, Feyza | |
dc.contributor.author | Ataseven, Hüseyin | |
dc.contributor.author | Akdoğan, Meral | |
dc.contributor.author | Kıyıcı, Murat | |
dc.contributor.author | Köksal, Aydın Şeref | |
dc.contributor.author | Akhan, Sila | |
dc.contributor.author | Günsar, Fülya | |
dc.contributor.author | Tabak, Fehmi | |
dc.contributor.author | Kaymakoglu, Sabahattin | |
dc.contributor.author | Akarca, Ulus S. | |
dc.contributor.author | Akarsu, Mesut | |
dc.contributor.author | Alkim, Hüseyin | |
dc.contributor.author | Araz, Filiz | |
dc.contributor.author | Ateş, Fehmi | |
dc.contributor.author | Aygen, Bilgehan | |
dc.contributor.author | Balık, İsmail | |
dc.contributor.author | Barut, Hüseyin S. | |
dc.contributor.author | Baysal, Birol | |
dc.contributor.author | Bolat, Aylin | |
dc.contributor.author | Çelik, İlhami | |
dc.contributor.author | Coşgun, Süleyman | |
dc.contributor.author | Ensaroglu, Fatih | |
dc.contributor.author | Gökcan, Hale | |
dc.contributor.author | Gürel, Selim | |
dc.contributor.author | Gürsoy, Şebnem | |
dc.contributor.author | İnkaya, Ahmet Çağan | |
dc.contributor.author | Kamilli, Cemil | |
dc.contributor.author | Kav, Taylan | |
dc.contributor.author | Kuruüzüm, Ziya | |
dc.contributor.author | Önder, Fatih O. | |
dc.contributor.author | Örmeci, Necati | |
dc.contributor.author | Özbakır, Ömer | |
dc.contributor.author | Özenirler, Seren | |
dc.contributor.author | Özer, Birol | |
dc.contributor.author | Özkan, Hasan | |
dc.contributor.author | Poturoğlu, Şule | |
dc.contributor.author | Senates, Ebubekir | |
dc.contributor.author | Şimşek, Halis | |
dc.contributor.author | Toka, Bilal | |
dc.contributor.author | Ünal, Hakan | |
dc.contributor.author | Yaras, Serkan | |
dc.contributor.author | Yıldırım, Abdullah E. | |
dc.contributor.author | Yıldırım, Beytullah | |
dc.contributor.author | Yılmaz, Bülent | |
dc.contributor.author | Yılmaz, Hasan | |
dc.contributor.author | Yozgat, Ahmet | |
dc.contributor.author | Yurdaydın, Cihan | |
dc.contributor.author | Early Access Program EAP Study Grp | |
dc.contributor.buuauthor | KIYICI, MURAT | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı | |
dc.contributor.orcid | 0000-0002-3208-6211 | |
dc.contributor.researcherid | AAI-4213-2021 | |
dc.date.accessioned | 2024-07-24T10:45:55Z | |
dc.date.available | 2024-07-24T10:45:55Z | |
dc.date.issued | 2019-06-01 | |
dc.description.abstract | The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P<0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P=0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC.Ledipasvir and sofosbuvir with or without ribavirin is an effective and tolerable treatment in hepatitis C virus-infected patients with advanced liver disease. Eradication is associated with improvements in liver function and reduces the risk of developing a new occurrence of hepatocellular carcinoma. | |
dc.identifier.doi | 10.1111/jvh.13075 | |
dc.identifier.eissn | 1365-2893 | |
dc.identifier.endpage | 674 | |
dc.identifier.issn | 1352-0504 | |
dc.identifier.issue | 6 | |
dc.identifier.startpage | 666 | |
dc.identifier.uri | https://doi.org/10.1111/jvh.13075 | |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1111/jvh.13075 | |
dc.identifier.uri | https://hdl.handle.net/11452/43412 | |
dc.identifier.volume | 26 | |
dc.identifier.wos | 000469027000006 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Wiley | |
dc.relation.journal | Journal of Viral Hepatitis | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Sustained virological response | |
dc.subject | Unexpected high-incidence | |
dc.subject | Acting antiviral therapy | |
dc.subject | All-cause mortality | |
dc.subject | Virus-infection | |
dc.subject | Plus ribavirin | |
dc.subject | Risk-factors | |
dc.subject | Genotype 1 | |
dc.subject | Liver | |
dc.subject | Hcv | |
dc.subject | Cirrhosis | |
dc.subject | Direct-acting antivirals | |
dc.subject | Hepatitis c virus | |
dc.subject | Hepatocellular carcinoma | |
dc.subject | Liver transplantation | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Gastroenterology & hepatology | |
dc.subject | Infectious diseases | |
dc.subject | Virology | |
dc.title | Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort | |
dc.type | Article | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | b364b52b-c416-4987-b080-93f6f81ecb3e | |
relation.isAuthorOfPublication.latestForDiscovery | b364b52b-c416-4987-b080-93f6f81ecb3e |